CR20130178A - COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0.]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3 - Google Patents

COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0.]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3

Info

Publication number
CR20130178A
CR20130178A CR20130178A CR20130178A CR20130178A CR 20130178 A CR20130178 A CR 20130178A CR 20130178 A CR20130178 A CR 20130178A CR 20130178 A CR20130178 A CR 20130178A CR 20130178 A CR20130178 A CR 20130178A
Authority
CR
Costa Rica
Prior art keywords
phenylsulphanylme
mglur
antagonists
hexane
substituted
Prior art date
Application number
CR20130178A
Other languages
English (en)
Inventor
Stephon Cornell Smith
Renhua Li
Charles Howard Mitch
Tatiana Natali Vetman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45099188&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130178(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20130178A publication Critical patent/CR20130178A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/18All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN ANTAGONISTA DEL RECEPTOR mGlu2/3 DE LA FÓRMULA, SE DESCRIBEN SUS USOS, Y MÉTODOS PARA SU PREPARACIÓN.-
CR20130178A 2010-11-18 2013-04-24 COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0.]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3 CR20130178A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41512110P 2010-11-18 2010-11-18
PCT/US2011/060730 WO2012068067A1 (en) 2010-11-18 2011-11-15 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists

Publications (1)

Publication Number Publication Date
CR20130178A true CR20130178A (es) 2013-07-09

Family

ID=45099188

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130178A CR20130178A (es) 2010-11-18 2013-04-24 COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0.]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3

Country Status (36)

Country Link
US (1) US8629169B2 (es)
EP (1) EP2640697B1 (es)
JP (1) JP5877847B2 (es)
KR (2) KR20150140876A (es)
CN (1) CN103228625B (es)
AR (1) AR083845A1 (es)
AU (1) AU2011329076B2 (es)
BR (1) BR112013012118A2 (es)
CA (1) CA2818116C (es)
CL (1) CL2013001345A1 (es)
CO (1) CO6761385A2 (es)
CR (1) CR20130178A (es)
DK (1) DK2640697T3 (es)
DO (1) DOP2013000099A (es)
EA (1) EA021724B1 (es)
EC (1) ECSP13012629A (es)
ES (1) ES2650139T3 (es)
GT (1) GT201300126A (es)
HR (1) HRP20171649T1 (es)
HU (1) HUE037457T2 (es)
IL (1) IL225843A (es)
LT (1) LT2640697T (es)
MA (1) MA34663B1 (es)
MX (1) MX339973B (es)
NO (1) NO2640697T3 (es)
NZ (1) NZ609816A (es)
PE (1) PE20140997A1 (es)
PL (1) PL2640697T3 (es)
PT (1) PT2640697T (es)
RS (1) RS56535B1 (es)
SG (1) SG189959A1 (es)
SI (1) SI2640697T1 (es)
TW (1) TWI520935B (es)
UA (1) UA110039C2 (es)
WO (1) WO2012068067A1 (es)
ZA (1) ZA201302918B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079343A1 (es) * 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
CA3019097C (en) 2016-04-18 2023-08-29 Taisho Pharmaceutical Co., Ltd. Prodrug of amino acid derivative
JP2020506895A (ja) 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0669928B2 (ja) 1987-10-06 1994-09-07 宇部興産株式会社 光重合性歯科材料
JP2589812B2 (ja) 1989-07-05 1997-03-12 松下電器産業株式会社 スチームアイロン
ZA969485B (en) 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
AU703093B2 (en) * 1995-11-16 1999-03-18 Eli Lilly And Company Excitatory amino acid receptor antagonists
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
TR200002671T2 (tr) * 1998-03-17 2000-12-21 Pfizer Products Inc. Bisiklo(2.2.1)Heptanlar ve ilgili bileşikler
GB9815542D0 (en) 1998-07-17 1998-09-16 Lilly Co Eli Bicyclohexane derivatives
CH694053A5 (de) 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
KR20090031962A (ko) 2001-12-27 2009-03-30 다이쇼 세이야꾸 가부시끼가이샤 6-플루오로비시클로[3.1.0]헥산 유도체
BR0311558A (pt) * 2002-06-11 2007-04-27 Lilly Co Eli composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
JP2007063129A (ja) 2003-06-26 2007-03-15 Taisho Pharmaceut Co Ltd 2−アミノ−3−アルコキシビシクロ[3.1.0]ヘキサン誘導体
WO2005000791A1 (ja) 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. 2-アミノ-ビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸エステル誘導体
AR079343A1 (es) * 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico

Also Published As

Publication number Publication date
AU2011329076B2 (en) 2015-03-12
HUE037457T2 (hu) 2018-08-28
SG189959A1 (en) 2013-06-28
NO2640697T3 (es) 2018-02-17
ECSP13012629A (es) 2013-07-31
CO6761385A2 (es) 2013-09-30
PL2640697T3 (pl) 2018-02-28
CA2818116C (en) 2016-04-05
EA201390498A1 (ru) 2013-07-30
EP2640697A1 (en) 2013-09-25
US20120129902A1 (en) 2012-05-24
CA2818116A1 (en) 2012-05-24
JP2014505664A (ja) 2014-03-06
KR20150140876A (ko) 2015-12-16
GT201300126A (es) 2014-02-27
IL225843A0 (en) 2013-06-27
EA021724B1 (ru) 2015-08-31
TW201307271A (zh) 2013-02-16
US8629169B2 (en) 2014-01-14
JP5877847B2 (ja) 2016-03-08
CN103228625A (zh) 2013-07-31
BR112013012118A2 (pt) 2016-09-27
UA110039C2 (xx) 2015-11-10
KR20130101094A (ko) 2013-09-12
WO2012068067A1 (en) 2012-05-24
RS56535B1 (sr) 2018-02-28
LT2640697T (lt) 2018-01-10
MX339973B (es) 2016-06-20
NZ609816A (en) 2014-12-24
AR083845A1 (es) 2013-03-27
DOP2013000099A (es) 2013-08-15
MX2013005622A (es) 2013-07-05
PT2640697T (pt) 2017-12-11
PE20140997A1 (es) 2014-08-25
ES2650139T3 (es) 2018-01-17
HRP20171649T1 (hr) 2017-12-15
EP2640697B1 (en) 2017-09-20
ZA201302918B (en) 2014-10-29
DK2640697T3 (en) 2017-10-23
CN103228625B (zh) 2014-12-03
AU2011329076A1 (en) 2013-05-02
MA34663B1 (fr) 2013-11-02
CL2013001345A1 (es) 2013-11-15
TWI520935B (zh) 2016-02-11
IL225843A (en) 2015-05-31
SI2640697T1 (sl) 2017-11-30

Similar Documents

Publication Publication Date Title
DOP2012000135A (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
GB201017345D0 (en) Receptor antagonists
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
CU24094B1 (es) Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3)
ECSP12012221A (es) Anticuerpos anti-cd40
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
MX2014010849A (es) Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
UY34572A (es) Compuestos heterocíclicos agonistas del receptor ip
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
CR20130178A (es) COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0.]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3
BR112013028511A2 (pt) receptor de sinais de radiofrequência
CO6470820A2 (es) Espiro-epóxidos como productos intermedios
HK1178902A1 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin b1 receptor b1
ES2636441T8 (es) Un procedimiento novedoso para la síntesis de polifenoles
HK1207855A1 (en) Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists (trp)
GT201200328A (es) Intermedios de agomelatina y método de preparación de éstos
CL2015000038A1 (es) Métodos para preparar triazolopiridinas sustituidas y compuestos intermediarios.
BR112013012384A2 (pt) compostos 3-benzilóóxi-biciclo[3.1.0]hexano 4-substituídos como antagonistas receptores de mglu2 e mglu3
EP3046923A4 (en) Formulations for cgrp receptor antagonists
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
HK1208028A1 (en) Novel acetamide derivatives as trp channel antagonists trp
TN2013000209A1 (en) 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists
UA54879U (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиоксидантного действия
ES2421810R1 (es) Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina